Search results for " Hepatocellular Carcinoma"

showing 10 items of 117 documents

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2021

Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the…

Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performanceCancers
researchProduct

Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

2021

Abstract Aim This study investigated how material deprivation in Italy influences the stage of hepatocellular carcinoma (HCC) at diagnosis and the chance of cure. Methods 4114 patients from the Italian Liver Cancer database consecutively diagnosed with HCC between January 2008 and December 2018 were analysed about severe material deprivation (SMD) rate tertiles of the region of birth and region of managing hospitals, according to the European Statistics on Income and Living Conditions. The main outcomes were HCC diagnosis modalities (during or outside surveillance), treatment adoption and overall survival. Results In more deprived regions, HCC was more frequently diagnosed during surveillan…

Cancer Researchmedicine.medical_specialtySettore MED/12 - GastroenterologiaDeprivationbusiness.industryHepatocellular carcinomaPrognosiHazard ratioDeprivation; Hepatocellular carcinoma; Overall survival; Prognosis; Social determinants of healthmedicine.diseasePrognosisSocial determinants of healthOncologyInternal medicineHepatocellular carcinomamedicineOverall survivalOverall survivalSocial determinants of healthStage (cooking)businessLiver cancerSocioeconomic status
researchProduct

Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after live…

2022

BackgroundThough the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT.MethodsWe retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT…

Cancer ResearchneoangiogenesisimmunocytochemistryrecurrenceOncologyliver transplantationneoangiogenesiangiopoietin-2hepatocellular carcinomaangiopoietin-2; hepatocellular carcinoma; immunocytochemistry; liver transplantation; neoangiogenesis; recurrence; survivalsurvival
researchProduct

The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells though redox-dependent signaling

2009

Cancer cells hepatocellular carcinoma NF-kB inhibitorSettore MED/06 - Oncologia Medica
researchProduct

Prioritization of high-cost new drugs for HCV: making sustainability ethical

2016

Hepatitis C virus (HCV) infection is a major health problem worldwide. Chronic HCV infection may in the long run cause cirrhosis, hepatic decompensation and hepatocellular carcinoma, with an ultimate disease burden of at least 350,000 deaths per year worldwide. The new generation of highly effective direct acting antivirals (DAA) to treat HCV infection brings major promises to infected patients in terms of exceedingly high rates of sustained virological response (SVR) but also of tolerability, allowing even the sickest patients to be treated. Even in the face of the excellent safety and efficacy and wide theoretical applicability of these regimens, their introduction is currently facing cos…

Carcinoma HepatocellularHealth PrioritiesLiver NeoplasmsInterferon-alphaHepacivirusHepatitis C ChronicAntiviral AgentsHepatitis CDrug CostsSettore MED/02 - Storia Della MedicinaAccess to care cirrhosis Direct acting antivirals Distributive justice Ethics Hepatitis C Hepatocellular carcinoma PrioritizationSettore MED/43 - Medicina LegaleQuality of LifeAnimalsHumansDrug Therapy Combinationhepatitis C
researchProduct

Analysis of Possible Mechanisms Accounting for Raf-1 Kinase Inhibitor Protein Downregulation in Hepatocellular Carcinoma

2012

Abstract Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor that promotes drug-induced apoptosis in cancer cells. It is frequently downregulated, both at the mRNA and protein level, in hepatocellular carcinoma (HCC), but the mechanisms leading to this reduction are obscure. We sequenced the whole RKIP gene in three human HCC cell lines (HA22T/VGH, HepG2, and Hep3B), and in five clinical HCC samples, but could not find any gene variant that might account for their low RKIP levels. We also examined whether gene methylation may be responsible for the altered RKIP expression. No methylation of the RKIP gene was found in the tumor samples, while among the cell lines only …

Carcinoma HepatocellularLeupeptinsAntineoplastic AgentsPhosphatidylethanolamine Binding ProteinRKIP (Raf-1 kinase inhibitor protein) hepatocellular carcinomaBiologyBiochemistryDownregulation and upregulationRNA interferenceCell Line TumorGeneticsHumansMetastasis suppressorPromoter Regions GeneticMolecular BiologyRegulation of gene expressionKinaseLiver NeoplasmsHep G2 CellsMethylationDNA Methylationdigestive system diseasesGene Expression Regulation NeoplasticMicroRNAsMutationCancer cellDNA methylationAzacitidineSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineRNA InterferenceBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

2021

Simple Summary Accurate prognostic systems capable of predicting the survival of patients with advanced hepatocellular carcinoma undergoing Sorafenib therapy are still lacking. The search for the ideal predictive tool for survival and drug response is justified by the recent availability of several other drugs effective for these patients, licensed as first- and second-line treatment, other than reducing adverse events and costs. In this study, we aimed to identify simple demographic and clinical parameters able to predict survival and Sorafenib response in a large multicenter cohort. In this study, we showed that patient’s general status, liver function and damage laboratory parameters and…

Cohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; SurvivalSorafenibOncologyCancer Researchmedicine.medical_specialtyPrognosisurvivalArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecohort studyRC254-282Settore MED/12 - GastroenterologiaPerformance statusProportional hazards modelbusiness.industryHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomaNomogrammedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologysorafenibprognosisLiver cancerbusinessmedicine.drugCancers
researchProduct

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

2014

Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…

DrugCarcinoma HepatocellularHepatocellular carcinomamedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceAntineoplastic AgentsBioengineeringPharmacologyApplied Microbiology and BiotechnologyCell Line TumormedicineHumansEpidermal growth factor receptorNanostructured lipid carriers Tyrphostin AG-1478 Drug release Hepatocellular carcinoma EGFR inhibitor.media_commonEGFR inhibitorsDrug CarriersNanostructured lipid carriersbiologyChemistryResearchLiver NeoplasmsCorrectionDrug releaseTyrphostinsmedicine.diseaseLipidsTyrphostin AG-1478Molecular medicineIn vitroNanostructuresErbB ReceptorsEGFR inhibitorLiverSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomaDrug deliveryQuinazolinesbiology.proteinMolecular MedicineDrug carrier
researchProduct

Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI.

2022

Abstract Background To investigate whether fractal analysis of perfusion differentiates hepatocellular adenoma (HCA) subtypes and hepatocellular carcinoma (HCC) in non-cirrhotic liver by quantifying perfusion chaos using four-dimensional dynamic contrast-enhanced magnetic resonance imaging (4D-DCE-MRI). Results A retrospective population of 63 patients (47 female) with histopathologically characterized HCA and HCC in non-cirrhotic livers was investigated. Our population consisted of 13 hepatocyte nuclear factor (HNF)-1α-inactivated (H-HCAs), 7 β-catenin-exon-3-mutated (bex3-HCAs), 27 inflammatory HCAs (I-HCAs), and 16 HCCs. Four-dimensional fractal analysis was applied to arterial, portal v…

Fractals Perfusion Hepatocellular adenoma Hepatocellular carcinoma Magnetic resonance imagingRadiology Nuclear Medicine and imagingInsights into imaging
researchProduct

GRP78 POLYMORPHISM rs430397 IS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN A SOUTHERN ITALIAN POPULATION

2014

GRP78 POLYMORPHISM HEPATOCELLULAR CARCINOMA ITALIAN POPULATION
researchProduct